The cloning of a cDNA for the human androgen receptor gene has resulted in
Male pseudohermaphroditism in humans is defined as a condition of incomplete masculinization of the fetal external genitalia in a karyotypically normal 46,XY individual (1) . Among the multiple genetic disorders that result in male pseudohermaphroditism are a group of abnormalities of the androgen target cells, including Sa-reductase deficiency and androgen insensitivity (2, 3) . The androgen insensitivity syndrome (AIS) is an X chromosome-linked disorder (4, 5) resulting from impairment of the biological actions of androgenic hormones related to defects in the intracellular androgen receptor (6) (7) (8) . Phenotypic expression is quite variable ranging from complete female phenotype to male genitalia with mild hypospadias (9, 10) . Recent evidence suggests that the syndrome includes some rare cases of phenotypically normal males with infertility (11, 12) . The heterogeneity in phenotypic expression is due to the variety of androgen receptor defects, some of which are detectable by biochemical methods (13) (14) (15) .
In the complete form ofAIS, affected subjects present with completely female external genitalia, but with a short vagina and absent Mullerian ducts; with normal-size testes located in the abdominal or inguinal area, but with hypoplastic Wolffian ducts; with normal female secondary-sex characteristics at puberty, but usually sparse or absent pubic and body hair (2, 3, 9) . In adults, serum testosterone and lutropin concentrations are at or above the normal adult male range (16) . Determination of androgen receptor binding in cultured genital skin fibroblasts has demonstrated the genetic heterogeneity of complete AIS, some patients having undetectable binding, or the so-called receptor (-) form, whereas others have quantitatively normal binding, termed the receptor (+) form (15, 17, 18) .
Cloning and partial analysis of human cDNA encoding the androgen receptor gene has been reported (19, 20) . Various fragments of the cDNA have been used in the present study to probe the genome of six unrelated patients with the receptor ( -) form of complete AIS. Five patients had normal restriction fragment patterns with EcoRI and BamHI endonucleases, suggesting a point mutation (or small, undetected deletion) of their androgen receptor gene. In one subject and her affected sibling, a partial deletion of the gene was observed, demonstrating further genetic heterogeneity in receptor (-), complete AIS. A preliminary report of this work has been presented. 11 MATERIALS AND METHODS Experimental Subjects. Informed written consent was obtained from each subject according to Johns Hopkins Institutional Guidelines for Clinical Investigation. We have studied 10 normal subjects (6 females and 4 males) and 1 affected individual from each of six unrelated families with the receptor (-) form of complete AIS. Several members of one of the families were also studied. The pedigree of this family is shown in Fig. 1 . The father is deceased and the mother (1-2) was shown to be heterozygous for the androgen receptor gene mutation (4 11-3 and 11-4 , and a sibling, 11-7. were 36.4 and 57.0 milliinternational units/ml (normal male = 8.9 + 3.5 milliinternational units/ml), respectively (patients 3 and 4 of ref. 21 ). Dihydrotestosterone receptor binding was absent in skin fibroblasts cultured from subjects 11-3 and II-4 but present at normal levels in a sexually normal brother , in two younger sisters (II-8 and II-9), and in their mother (I-2), an obligate heterozygote (4). Five subjects from this family, 1-2, II-2, 11-3, II-4, and II-9, are included in this study.
Hybridization Probes. Two of the hybridization probes for the androgen receptor, hAR-1 and hAR-2, were derived from clone ARHFLlH-X obtained from a human foreskin fibroblast cDNA library as described by Lubahn et al. (20) . ARHFLlH-X contains a portion of the DNA-binding domain as determined from nucleotide sequence data. When cloned into the expression vector pCMV, ARHFLlH-X also synthesizes a protein that binds dihydrotestosterone specifically and with high affinity. As shown in Fig. 2 , hAR-1 is a 718-base pair (bp) cDNA fragment containing a portion of the DNAbinding domain at its 5' terminus and extending toward the 3' steroid-binding domain. hAR-2 is a 490-bp cDNA contiguous with hAR-1 and contains the extreme 3' coding sequence and some of the 3' noncoding region. hAR-3 is a 575-bp cDNA fragment derived from clone gtll ARHEL1 that was isolated from a human epididymal cDNA library and localized on the 5' side ofthe DNA-binding region ofthe gene and 560 bp from the putative initiation start site for transcription (20) . The human coagulation factor VIII DNA probe was a 5.4-kilobase pair (kb) genomic fragment from exon 26 of this gene, kindly provided by Stylios Antonarakis (Johns Hopkins University). All DNA probes were radiolabeled to a specific activity of 109 cpm/,tg of DNA with [a-32P]dCTP (New England Nuclear) by a random-priming method (22) .
DNA Restriction Analysis. Genomic DNA was isolated from peripheral leukocytes as described (23) and modified by our laboratory (24) . For extraction of DNA from skin fibroblasts, cells from 10 to 16 100-mm culture plates were trypsinized and removed by repeated pipetting with Trisbuffered saline (10 mM Tris HCI, pH 7.4/0.9% NaCl). Cells were collected by centrifugation at 800 x g for 5 min at 4°C. The cells were resuspended in 10 ml of Tris-buffered saline and resedimented. The cells were resuspended in 10 ml of a solution of 50 mM Tris HCl (pH 7.8), 0.15 M NaCl, and 5 mM EDTA, incubated in the presence of proteinase K (1-2 mg) for 15 min at 650C, and then incubated for an additional 12-16 hr at 370C with shaking. This solution was extracted three times with an equal volume (10 ml) of phenol/chloroform, 1: 1 (vol/vol), and twice with chloroform/isoamyl alcohol, 24: 1 (vol/vol). DNA was precipitated from the aqueous phase by the addition of 5 ml of 7.5 M ammonium acetate and 37.5 ml of ice-cold ethanol followed by centrifugation at 10,000 x g for 15 min at 4°C. The supernatant was decanted and the DNA pellet was washed with 5 ml of 80% (vol/vol) ethanol. DNA was dissolved in 5 ml of 10 mM Tris HCl (pH 7.4) plus 1 mM EDTA (TE) by shaking at 37°C for 12-16 hr. The solution was treated with RNase A (100 ,ug/ml) for 30 min at 37°C and reextracted twice with 5 ml of phenol/chloroform, 1:1 (vol/vol), once with chloroform, and once with chloroform/isoamyl alcohol, 24:1 (vol/vol). DNA was precipitated from the aqueous phase by the addition of 0.5 ml of 3 M sodium acetate and 12.5 ml of ice-cold ethanol followed by centrifugation at 10,000 x g for 15 min at 4°C. The pellet was washed with 5 ml of ice-cold 80% (vol/vol) ethanol and recentrifuged. DNA from leukocytes and skin fibroblasts was incubated in TE buffer at 37°C with shaking until dissolved and the concentration of each sample was determined spectrophotometrically.
DNA (8-10 jig) was digested for 16-20 hr with various restriction endonucleases according to the manufacturer's recommendations for buffer and temperature. DNA fragments were separated by agarose gel electrophoresis [1% (wt/vol)], transferred in alkaline buffer to GeneScreenPlus (DuPont/NEN), and neutralized on the membrane. The membrane was prehybridized overnight at 42°C in a solution containing 50% (vol/vol) deionized formamide, 5 x Denhardt's solution, 5 x SSPE, 1% NaDodSO4, 10% (wt/vol) deXtran sulfate, heparin (25 units/ml), 0.25 mM ATP, and denatured salmon sperm DNA (100 ,g/ml).
(1 x Denhardt's solution = 0.02% polyvinylpyrrolidone/0.02% Ficoll/0.02% bovine serum albumin; 1 x SSPE = 0.18 M NaCl/10 mM sodium phosphate, pH 7.4/1 mM EDTA.) Hybridization was performed by adding the radiolabeled cDNA probe in the same prehybridization solution to a final concentration of 106 cpm/ml and incubating at 42°C for 24-48 hr. The membranes were washed successively in (i) 2 x SSC/0.5% NaDodSO4 for two 15-min periods at 25°C, (ii) 2 x SSC/0.1% NaDodSO4 for three 10-min periods at 250C, and (iii) 0.1 x SSC/l.Oo NaDodSO4 for four 30-min periods at 68-70'C.
(1 x SSC = 0.15 M NaCI/0.015 M sodium citrate, pH 7.0.) The membranes were exposed to Kodak XAR-5 film with intensifying screens at -70'C for 3-10 days. Blots to be rehybridized with a second probe were first incubated three times with boiling 0.1 x SSC/0.5% NaDodSO4 and shaking to remove the original hybridization probe. To ensure complete removal of the probe, the blots were then exposed to XAR-5 film for 48 hr before rehybridization as described above.
RESULTS
Genomic DNA was extracted from cultured genital skin fibroblasts or leukocytes of 10 normal subjects and 6 subjects with the receptor (-) form of complete AIS. DNA was digested with the restriction endonuclease EcoRI or BamHI and analyzed by Southern blotting techniques and by hybridization with the hAR-1 probe. As shown in Fig. 3 Upper, two restriction fragments of 9.4 kb and 2.4 kb were observed after EcoRI digestion in 5 subjects (lanes A-E) with complete AIS and also observed in 10 normal male and female subjects (data not shown). However, subject II-3 showed only the 9.4-kb fragment, suggesting that part of the androgen receptor gene was missing. Further evidence for a partial deletion of the androgen receptor gene in subject II-3 was apparent after DNA digestion with BamHI ( Fig. 3 Lower). In 5 affected subjects (lanes A-E) and control subjects, the hAR-1 cDNA probe hybridized to restriction fragments of 7. .on fragments were absent. As a control, the radiolabeled hAR-1 cDNA probe was removed and the same blots were rehybridized with a radiolabeled 5.4-kb genomic DNA probe for the human factor VIII gene. This revealed the presence in all six affected subjects of the expected restriction fragments for EcoRI of 5.4 kb and for BamHI of 3.4 kb and 2.1 kb (data not shown).
Further documentation for a partial androgen receptor gene deletion was provided by DNA restriction fragment patterns of subject II-3 and other members of her family (Fig.  1) . DNA digested with EcoRI and hybridized with radiolabeled hAR-1 revealed the presence of two restriction fragments of 9.4 and 2.4 kb in the mother (1-2) and two normal female siblings, 11-2 and II-9 (Fig. 4 Top) , a pattern similar to that shown for three unrelated controls. Subject 11-3 and her affected nonidentical twin sibling showed no evidence of a 2.4-kb fragment. Rehybridization of this same DNA blot with radiolabeled hAR-2 cDNA as probe (Fig. 4 Middle) identified 1.2-and 0.7-kb restriction fragments in the three controls, in the mother (1-2) , and in the two unaffected female siblings (II-2 and 11-9). However, the 1.2-and 0.7-kb restriction fragments were absent in 11-3 and II-4. By contrast, rehybridization of this same DNA blot with radiolabeled hAR-3 cDNA probe revealed the presence of a restriction fragment of -23 kb for all subjects tested, including the two with complete AIS (Fig. 4 Bottom) . A control hybridization with the factor VIII probe confirmed that similar amounts of DNA were applied to each lane (data not shown). However, the detection of the heterozygous carriers (e.g., subject 1-2) Fig. 3 with complete AIS and of three control subjects (two females, one male). DNA (10 Jg) was digested with EcoRI and analyzed by hybridization with 32P-labeled hAR-1 (Top), hAR-2 (Middle), and hAR-3 (Bottom). 
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of the androgen receptor gene deletion in this family will require a more definitive assessment of gene dosage than that shown in Fig. 4 .
The three androgen receptor cDNAs were used to probe DNA fragments generated by BamHI digestion in members of the family with complete AIS and in control subjects (Fig.  5) . The radiolabeled hAR-1 cDNA probe hybridized with restriction fragments of 7.0, 6.0, 5.4, and 4.4 kb in normal subjects, the mother (1-2), and two unaffected siblings (II-2 and 11-9) (Fig. 5 Top) . However, 7.0-and 6.0-kb restriction fragments were absent in the two affected siblings (II-3 and II-4). Radiolabeled hAR-2 cDNA hybridized with a single 2.0-kb restriction fragment in DNA from normal subjects, the mother, and two unaffected siblings, but not from the two affected subjects (Fig. 5 Middle) . Rehybridization of this DNA blot with radiolabeled hAR-3 cDNA probe showed the presence of an -27-kb restriction fragment in all of the subjects examined (Fig. 5 Bottom) .
DISCUSSION
Complete unresponsiveness to androgens is known as AIS in humans and as the testicular feminization mutation in mice (25, 26) and rats (27, 28) . Linkage to the X chromosome was first suggested in rats by analysis of sex ratios (27, 28) , whereas the testicular feminization mutation in mice was mapped to a linkage group, including tabby and blotchy, that occupies the distal half of the murine X chromosome (25, 26) . Fig. 3 with complete AIS and of three control subjects (two females, one male). DNA (10 Ag) was digested with BamHI and analyzed by hybridization with 32P-labeled hAR-1 (Top), hAR-2 (Middle), and hAR-3 (Bottom). Xq13 . It has been shown that the androgen receptor structural gene indeed occupies this X chromosome locus (20) . Studies by Wieacker et al. (29) have also presented evidence for close linkage between the androgen receptor locus and DXS1 segment.
The androgen receptor belongs to the subfamily of steroid hormone receptors within a larger family of chromatinbinding proteins that are likely to have evolved from a common ancestral gene (for review, see ref. 30 ). The steroid receptor genes contain an amino-terminal region of variable length with a proposed role in transcriptional activation, a highly conserved central region rich in cysteine residues required of the zinc-binding finger structure that binds DNA, and a carboxyl-terminal region where ligand binding occurs. The cloning of cDNAs for the human androgen receptor gene (19, 20) provides the molecular tools to correlate structure and function and, specifically, to identify and relate the natural mutations occurring in AIS to the physiologic properties of androgen receptors.
In the present work, we elected to study patients with complete AIS who had undetectable androgen receptors by ligand binding assays (31) , in the expectation that some of them might present a deletion of the androgen receptor gene. About 5-10% of mutations found in genetic disorders are due to gene deletions (32) (33) (34) (35) . Assuming a 5% frequency, screening of 14 independent mutations of the androgen receptor gene should result in greater than a 50% chance of finding a gene deletion. Our group of patients included one affected subject from each of six unrelated families. One of them showed a definite deletion when using two endonucleases, EcoRI and BamHI. This finding demonstrates further genetic heterogeneity in AIS; some patients with the complete receptor (-) form have a deletion of the androgen receptor gene, whereas others have no detectable deletion when assessed by identical techniques. In the second group, the gene may not be expressed because of a point mutation or the mutant gene may express a receptor protein that is structurally modified so as to be unable to bind the androgen ligand.
Additional DNA restriction analysis was carried out in the patient with identifiable gene deletion and in members of her family. The use ofthree cDNA probes that spanned the entire receptor gene demonstrated that the deletion was partial but affected the entire steroid-binding domain. This was demonstrated by the absence of several restriction fragments that hybridized with hAR-1 cDNA, including the 5' portion of this domain, by the complete absence of the normal restriction fragments that hybridized with hAR-2 cDNA, including the 3' portion of the steroid-binding domain, but by a normal restriction fragment pattern with the hAR-3 cDNA probe, including a portion of the 5' amino-terminal domain (Fig. 2) of the androgen receptor. A dizygotic affected sister, two unaffected sisters, and the mother confirmed the relation of AIS and restriction fragments observed with the two endonucleases and the three cDNA probes used in the study.
In summary, we have identified a partial deletion of the human androgen receptor gene in a subject with complete AIS. The fact that cultured genital skin fibroblasts from this subject have undetectable androgen receptor binding activity is correlated with an apparent deletion in the 3' region of the gene that encodes the carboxyl terminus of the receptor protein responsible for androgen binding. Initial findings from other subjects with the receptor (-) form of complete AIS suggest that gross deletions within the steroid-binding domain of the receptor do not account for their target cell insensitivity and hence these mutations may form a heterogeneous group of molecular lesions.
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